{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T13:01:16Z","timestamp":1772542876989,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.clml.2021.03.003","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T03:14:34Z","timestamp":1616123674000},"page":"e626-e629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Concurrent TP53 Mutation and Deletion in Refractory Low-grade Follicular Lymphoma"],"prefix":"10.1016","volume":"21","author":[{"given":"Mahsa","family":"Khanlari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan H.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karan","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq","family":"Muzzafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beenu","family":"Thakral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.03.003_bib0001","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.clml.2021.03.003_bib0002","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus Rituximab or CHOP plus (131)I-Tositumomab: long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","author":"Shadman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.clml.2021.03.003_bib0003","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2021.03.003_bib0004","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.003_bib0005","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2021.03.003_bib0006","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2019-130208","article-title":"Evaluation of the m7-FLIPI in patients with follicular lymphoma treated within the Gallium trial: EZH2 mutation status may be a predictive marker for differential efficacy of chemotherapy","volume":"134","author":"Jurinovic","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.003_bib0007","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.2019000560","article-title":"Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles","volume":"135","author":"Staiger","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.003_bib0008","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.16159","article-title":"M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy","volume":"188","author":"Lockmer","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.03.003_bib0009","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"O'Shea","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.003_bib0010","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma","volume":"82","author":"Lo Coco","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.003_bib0011","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.V82.7.1994.1994","article-title":"p53 mutation is associated with progression in follicular lymphomas","volume":"82","author":"Sander","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.003_bib0012","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood.V88.4.1437.bloodjournal8841437","article-title":"High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma","volume":"88","author":"Bentz","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.003_bib0013","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.003_bib0014","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.gde.2010.10.002","article-title":"New plays in the p53 theater","volume":"21","author":"Aylon","year":"2011","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.clml.2021.03.003_bib0015","article-title":"TP53 mutations in nonsmall cell lung cancer","volume":"2011","author":"Mogi","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.clml.2021.03.003_bib0016","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halldorsdottir","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.03.003_bib0017","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2141.2009.07739.x","article-title":"The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target","volume":"146","author":"Cheung","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.03.003_bib0018","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood.V90.10.4078","article-title":"Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma","volume":"90","author":"Koduru","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.003_bib0019","first-page":"673","article-title":"Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation","volume":"39","author":"Symmans","year":"1995","journal-title":"Acta Cytol"},{"key":"10.1016\/j.clml.2021.03.003_bib0020","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.leu.2403802","article-title":"A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"19","author":"Davies","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.03.003_bib0021","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.htct.2020.05.005","article-title":"Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods","volume":"42","author":"Chauffaille","year":"2020","journal-title":"Hematol Transfus Cell Ther"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:30Z","timestamp":1761870990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021001038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2152265021001038"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.03.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concurrent TP53 Mutation and Deletion in Refractory Low-grade Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}